Recent Finacing
Recent Raise
Versanis Bio is a clinical-stage biotech developing bimagrumab, an anti-activin type II receptor monoclonal antibody to reduce fat mass while preserving lean mass and improving cardiometabolic measures.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Versanis Bio.
